Nostiriazyn

Active Ingredient:: Nitrofurantoin
Origin:: EU

Nostiriazyn (Nitrofurantoin)

Q: What is Nostiriazyn used for?

Nostiriazyn contains the antibiotic nitrofurantoin and is indicated for the treatment of uncomplicated urinary tract infections, including acute cystitis, in adult patients. It targets common uropathogenic bacteria to relieve symptoms such as pain, urgency, and frequency of urination.

Q: How does Nitrofurantoin work?

Nitrofurantoin is absorbed after oral intake and concentrates in the urine. It interferes with bacterial enzyme systems involved in carbohydrate metabolism and damages bacterial DNA, leading to either bacteriostatic or bactericidal activity against susceptible urinary pathogens.

Q: What is the usual dose of Nostiriazyn?

The dose of Nostiriazyn is determined by the prescribing clinician based on the severity of infection, renal function, and patient-specific factors. Healthcare professionals follow local guidelines and adjust the regimen as needed; patients should not alter the dose without medical advice.

Q: Is Nostiriazyn safe in pregnancy or breastfeeding?

Safety data for nitrofurantoin during pregnancy are limited, and the drug is generally avoided unless the benefits outweigh potential risks. It is excreted in breast milk, so caution is advised for nursing mothers. Consultation with a healthcare provider is essential before use.

Q: How do I order Nostiriazyn from GNH India?

To order Nostiriazyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Q: How does Nitrofurantoin compare with the main alternative drug or class?

Nitrofurantoin is often compared with trimethoprim‑sulfamethoxazole, another oral agent for uncomplicated urinary infections. Nitrofurantoin has a narrow spectrum focused on urinary pathogens and lower rates of systemic side effects, while trimethoprim‑sulfamethoxazole offers broader coverage but may cause more allergic reactions and drug interactions.

Q: How should Nostiriazyn be stored and handled?

Nostiriazyn tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Q: How is Nostiriazyn administered?

Nostiriazyn is taken orally with a full glass of water. It may be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing, especially if antacids are used, to ensure optimal absorption.

Q: What are the most serious risks to watch for while taking Nostiriazyn?

Serious adverse reactions include pulmonary toxicity (interstitial lung disease), severe liver injury, hemolytic anemia in individuals with G6PD deficiency, and rare skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent cough, shortness of breath, jaundice, dark urine, or severe rash.

Q: Who should not use Nostiriazyn?

Nostiriazyn should be avoided in patients with severe renal impairment (creatinine clearance <60 mL/min), known hypersensitivity to nitrofurantoin, or confirmed G6PD deficiency due to the risk of hemolysis. It is also contraindicated in individuals who have experienced previous serious pulmonary or hepatic reactions to the drug.

Nitrofurantoin, the active ingredient in Nostiriazyn, is a nitrofuran antibiotic presented as tablets for oral use. It is indicated for the treatment of uncomplicated urinary tract infections, primarily affecting the bladder, in adult patients. The drug works by interfering with bacterial enzyme systems and damaging bacterial DNA, leading to bacterial death.

GNH India supplies Nostiriazyn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product quality through strict regulatory compliance and provides reliable global logistics for qualified healthcare institutions.

Manufacturer / TM Owner

Olpha As

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Nitrofurantoin, the nitrofuran antibiotic in Nostiriazyn, is used to treat infections of the urinary tract caused by susceptible bacteria.

Uncomplicated urinary tract infection: eliminates the causative bacteria, relieving symptoms such as dysuria, frequency, and urgency.
Acute cystitis: provides rapid bactericidal activity against common uropathogens, leading to clinical cure.
Recurrent urinary tract infection prophylaxis: reduces the frequency of infection episodes when administered over a prolonged period.

How It Works

Nitrofurantoin is rapidly absorbed after oral administration and concentrated in the urine, where it exerts its antibacterial effect. It interferes with bacterial enzyme systems involved in carbohydrate metabolism and disrupts bacterial DNA synthesis, causing structural damage to bacterial DNA. These actions result in either bacteriostatic or bactericidal activity against susceptible urinary pathogens, particularly Escherichia coli and other Gram‑negative organisms such as Klebsiella and Proteus species.

Side Effects

Nitrofurantoin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

Nausea: mild stomach upset often occurring early in therapy.
Loss of appetite: reduced desire to eat during treatment.
Headache: transient pain in the head.
Diarrhea: loose stools that may be self‑limiting.
Dizziness: light‑headed sensation, especially when standing quickly.
Urinary discoloration: brownish urine due to drug metabolites.

Serious or Rare Side Effects

Pulmonary toxicity: interstitial lung disease presenting with cough and dyspnea.
Hepatotoxicity: liver enzyme elevations or hepatitis.
Hemolytic anemia: especially in patients with G6PD deficiency.
Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
Acute renal failure: sudden loss of kidney function.
Peripheral neuropathy: tingling or numbness in extremities.

Precautions & Warnings

Before prescribing Nitrofurantoin, clinicians should consider several safety and handling precautions.

Renal function: assess kidney function; avoid use if creatinine clearance is <60 mL/min.
Pregnancy: use only if clearly needed; safety data are limited.
G6PD deficiency: screen patients as hemolysis risk may increase.
Drug hypersensitivity: discontinue if rash, fever, or eosinophilia develop.
Concomitant medications: monitor for interactions that may affect drug levels.
Store at room temperature: keep tablets in the original container, protect from moisture and light.

Avoid Interactions

Nitrofurantoin can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid)

Antacids containing magnesium or aluminum: reduce absorption; separate dosing by at least 2 hours.
Probenecid: decreases renal excretion, raising plasma concentrations.
Fluoroquinolones: additive risk of tendon rupture when combined.

Moderate Interactions (Monitor Closely)

Warfarin: may enhance anticoagulant effect; monitor INR.
Diuretics: may increase risk of crystalluria; ensure adequate hydration.
NSAIDs: may affect renal function, altering drug clearance.

Frequently Asked Questions

Nostiriazyn contains the antibiotic nitrofurantoin and is indicated for the treatment of uncomplicated urinary tract infections, including acute cystitis, in adult patients. It targets common uropathogenic bacteria to relieve symptoms such as pain, urgency, and frequency of urination.

Nitrofurantoin is absorbed after oral intake and concentrates in the urine. It interferes with bacterial enzyme systems involved in carbohydrate metabolism and damages bacterial DNA, leading to either bacteriostatic or bactericidal activity against susceptible urinary pathogens.

The dose of Nostiriazyn is determined by the prescribing clinician based on the severity of infection, renal function, and patient-specific factors. Healthcare professionals follow local guidelines and adjust the regimen as needed; patients should not alter the dose without medical advice.

Safety data for nitrofurantoin during pregnancy are limited, and the drug is generally avoided unless the benefits outweigh potential risks. It is excreted in breast milk, so caution is advised for nursing mothers. Consultation with a healthcare provider is essential before use.

To order Nostiriazyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Nitrofurantoin is often compared with trimethoprim‑sulfamethoxazole, another oral agent for uncomplicated urinary infections. Nitrofurantoin has a narrow spectrum focused on urinary pathogens and lower rates of systemic side effects, while trimethoprim‑sulfamethoxazole offers broader coverage but may cause more allergic reactions and drug interactions.

Nostiriazyn tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Nostiriazyn is taken orally with a full glass of water. It may be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing, especially if antacids are used, to ensure optimal absorption.

Serious adverse reactions include pulmonary toxicity (interstitial lung disease), severe liver injury, hemolytic anemia in individuals with G6PD deficiency, and rare skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent cough, shortness of breath, jaundice, dark urine, or severe rash.

Nostiriazyn should be avoided in patients with severe renal impairment (creatinine clearance <60 mL/min), known hypersensitivity to nitrofurantoin, or confirmed G6PD deficiency due to the risk of hemolysis. It is also contraindicated in individuals who have experienced previous serious pulmonary or hepatic reactions to the drug.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.